With the development of immune checkpoint inhibitors, including programmed cell death-ligand 1 (PD-L1) and programmed cell death protein-1 (PD-1) inhibitors, the systemic therapy of non-small cell lung cancer (NSCLC) has entered the era of immunotherapy. Here, CD274 is linked to non-small cell lung carcinoma.